SEC Company Response from SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Aug 18, 2006

SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: Aug. 18, 2006 · CIK: 0000812796 · Accession: 0000812796-06-000049

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Referenced dates: August 15, 2006

Date

December 31, 2005

Author

/s/

Form

CORRESP

Company

SOLIGENIX, INC. (SNGX) (CIK 0000812796)

Letter

Division of Corporation Finance United States Securities and Exchange Commission F Street, NE Washington, D.C. 20549 RE: Review of Filings and comments related to Form 10KSB for the Fiscal Year Ended December 31, 2005 and Form 10QSB for the Fiscal Quarter Ended June 30, 2006.

Dear Ms. Buckner,

Thank you for the opportunity to work with you and discuss the disclosure requirements. This letter is in response to your letter dated August 15, 2006. We are requesting that the response date be extended to September 8, 2006. Currently, we are in the process of moving the offices and expect to be in the new offices by early next week; in addition our auditors are on an audit in Boston and will not be fully accessible until next week.

If you should have any questions please call me at 305-534-3383.

Sincerely,
/s/
Evan Myrianthopoulos_

Show Raw Text

CORRESP
1
filename1.htm

      DOR Extension letter

    DOR
      BioPharma, Inc.

    August
      18, 2006

    SENT
      VIA EDGAR

    Amy
      C. Buckner

    Staff
      Accountant

    Division
      of Corporation Finance

    United
      States Securities and Exchange Commission

    100
      F
      Street, NE

    Washington,
      D.C. 20549

    RE:
      Review of Filings and comments related to Form 10KSB for the Fiscal Year Ended
      December 31, 2005 and Form 10QSB for the Fiscal Quarter Ended June 30, 2006.

    Dear
      Ms.
      Buckner,

    Thank
      you
      for the opportunity to work with you and discuss the disclosure requirements.
      This letter is in response to your letter dated August 15, 2006. We are
      requesting that the response date be extended to September 8, 2006. Currently,
      we are in the process of moving the offices and expect to be in the new offices
      by early next week; in addition our auditors are on an audit in Boston and
      will
      not be fully accessible until next week.

    If
      you
      should have any questions please call me at 305-534-3383.

    Sincerely,

    /s/
      Evan Myrianthopoulos_

    Evan
      Myrianthopoulos

    Chief
      Financial Officer

    DOR
      BioPharma, Inc.

    MD/AMEX/EC

SecProbe.io